Recruiting
Phase 1
Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Sponsor:

Boehringer Ingelheim

Code:

NCT06324357

Conditions

Metastatic Breast Cancer

Metastatic Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Esophageal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zongertinib

Trastuzumab deruxtecan

Trastuzumab emtansine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information